Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment...( Ferring Pharmaceuticals and Ferring R...)

Ferring Pharmaceuticals and Ferring Research Institute Introduce New Research Base and First Molecule Discovered by the Company in San Diego

SAN DIEGO, Feb. 11 /PRNewswire/ -- Leading global biopharmaceutical company, Ferring Pharmaceuticals, and its affiliate Ferring Research Institute have opened a new and expanded, 38,000-square-foot facility located in Sorrento Valley, San Diego that will be dedicated to further development of peptide research and therapeutics.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090211/LA63509)

The new facility was introduced at an event yesterday attended by global executives and top U.S. academic and research collaborators. They included: Nobel Laureate and Interim President for The Salk Institute, Professor Roger Guillemin; Chair and Professor of Medicine, Department of Medicine at Columbia University, Professor Donald Landry; Dean and Professor of Physiology and Medicine at Tufts University School of Medicine, Professor Michael Rosenblatt; representatives from the City of San Diego; and, members of the local biotech community.

The occasion also marked recognition for the recent approval by the U.S. Food and Drug Administration (FDA) of degarelix, a new prostate cancer drug for the treatment of patients with advanced hormone-dependent prostate cancer. Degarelix is the first peptide new chemical entity (NCE) discovered by Ferring Research Institute in San Diego and developed globally by Ferring Pharmaceuticals. Ferring is preparing to launch degarelix in the U.S. in the first quarter of 2009.

Ferring is a privately held global biopharmaceutical company focused on the discovery, development and marketing of biologics, peptides and proteins. The company's research is dedicated to three core therapeutic areas--Infertility, Urology and Gastroe
'/>"/>